Neotigason (Acitretin)

Acitretin binds to nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR), altering gene expression that controls epidermal cell differentiation and proliferation. This modulation reduces hyperkeratinisation and inflammation, leading to smoother skin.

The dose of Neotigason is individualized by the prescribing clinician based on disease severity, patient weight and response. Typically a low starting dose is chosen and may be titrated upward under medical supervision, with regular monitoring of liver function and lipids.

Acitretin is classified as pregnancy category X because it is highly teratogenic. It must not be used by pregnant women or women who may become pregnant, and effective contraception is required for at least three years after discontinuation. Use during breastfeeding is also contraindicated.

To order Neotigason, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternatives for severe psoriasis include methotrexate, cyclosporine and biologic agents such as TNF‑α inhibitors. Unlike immunosuppressants, acitretin is a retinoid that primarily normalises keratinocyte differentiation and does not suppress the immune system, but it carries a higher risk of teratogenicity and lipid abnormalities.

Neotigason should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Neotigason is taken orally, usually with a meal to improve tolerability. Tablets should be swallowed whole with water and not crushed or chewed. The exact schedule—once daily or divided doses—depends on the prescriber’s instructions.

The most critical risks include severe teratogenicity, hepatotoxicity, marked hyperlipidaemia, bone toxicity such as premature epiphyseal closure, and rare events like pseudotumor cerebri or severe cutaneous reactions. Patients should report any signs of liver dysfunction, unusual lipid changes or neurological symptoms promptly.

Neotigason is contraindicated in pregnant women, women planning pregnancy, and anyone unable to use reliable contraception for the required period. It should also be avoided in patients with severe liver disease, uncontrolled hyperlipidaemia, active bone disorders, or known hypersensitivity to acitretin or other retinoids.